📊 COCHW Key Takeaways
Is Envoy Medical, Inc. (COCHW) a Good Investment?
Envoy Medical is in critical financial distress with negative stockholders' equity of -$7.7M, indicating technical insolvency. The company is burning cash at an alarming rate (-$12.5M operating cash flow) while generating minimal revenue ($166K), demonstrating fundamental operational failure and inability to sustain operations without immediate capital intervention.
Envoy Medical's fundamentals are extremely weak: revenue is negligible and declining, while operating and net losses remain many multiples of sales. The balance sheet is distressed with negative equity, sub-1.0 liquidity ratios, and ongoing cash burn that appears unsustainable without external financing.
Why Buy Envoy Medical, Inc. Stock? COCHW Key Strengths
- Maintains $3.6M cash position providing short-term liquidity runway
- Recent insider Form 4 filings (8 in last 90 days) suggest management engagement
- Modest capital expenditure ($7K) indicates discipline in avoiding additional capex drain
- Net loss and diluted EPS improved year over year, indicating some reduction in loss intensity
- Cash balance of $3.56M provides limited near-term operating flexibility
- Capital expenditure is minimal, which reduces additional cash demands from investment spending
COCHW Stock Risks: Envoy Medical, Inc. Investment Risks
- Negative stockholders' equity of -$7.7M represents technical insolvency and existential solvency risk
- Severe operating losses (-$15.9M) with revenue declining 28.8% YoY indicates deteriorating core business
- Negative operating cash flow of -$12.5M with only $3.6M cash suggests runway of approximately 3 months at current burn rate
- Current ratio of 0.64x and quick ratio of 0.46x indicate acute liquidity crisis and inability to meet short-term obligations
- Liabilities exceed assets by $7.5M, creating structural insolvency
- Revenue fell 28.8% year over year and remains far too small to support the cost structure
- Negative stockholders' equity and weak current/quick ratios signal material financial stress
- Operating cash flow of -$12.52M implies continued dependence on outside capital to fund operations
Key Metrics to Watch
- Cash balance and runway timeline - critical for going concern assessment
- Monthly operating cash burn rate and trajectory
- Revenue stabilization or decline acceleration - fundamental viability indicator
- Restructuring announcements or financing activities indicating recapitalization attempts
- Quarterly cash position trend to assess proximity to insolvency
- Revenue growth and commercialization traction
- Quarterly operating cash burn relative to cash on hand
Envoy Medical, Inc. (COCHW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
COCHW Profit Margin, ROE & Profitability Analysis
COCHW vs Healthcare Sector: How Envoy Medical, Inc. Compares
How Envoy Medical, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Envoy Medical, Inc. Stock Overvalued? COCHW Valuation Analysis 2026
Based on fundamental analysis, Envoy Medical, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Envoy Medical, Inc. Balance Sheet: COCHW Debt, Cash & Liquidity
COCHW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Envoy Medical, Inc.'s revenue has declined by 24% over the 5-year period, indicating business contraction. The most recent EPS of $-1.49 indicates the company is currently unprofitable.
COCHW Revenue Growth, EPS Growth & YoY Performance
COCHW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $42.0K | -$3.9M | $-0.35 |
| Q2 2025 | $68.0K | -$3.9M | $-0.29 |
| Q1 2025 | $46.0K | -$5.0M | $-0.29 |
| Q3 2024 | $56.0K | $1.6M | $0.13 |
| Q2 2024 | $63.0K | -$3.9M | $-0.27 |
| Q1 2024 | $59.0K | -$6.3M | $-0.32 |
| Q3 2023 | $57.0K | -$1.2M | $-0.13 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Envoy Medical, Inc. Dividends, Buybacks & Capital Allocation
COCHW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Envoy Medical, Inc. (CIK: 0001840877)
📋 Recent SEC Filings
❓ Frequently Asked Questions about COCHW
What is the AI rating for COCHW?
Envoy Medical, Inc. (COCHW) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are COCHW's key strengths?
Claude: Maintains $3.6M cash position providing short-term liquidity runway. Recent insider Form 4 filings (8 in last 90 days) suggest management engagement. ChatGPT: Net loss and diluted EPS improved year over year, indicating some reduction in loss intensity. Cash balance of $3.56M provides limited near-term operating flexibility.
What are the risks of investing in COCHW?
Claude: Negative stockholders' equity of -$7.7M represents technical insolvency and existential solvency risk. Severe operating losses (-$15.9M) with revenue declining 28.8% YoY indicates deteriorating core business. ChatGPT: Revenue fell 28.8% year over year and remains far too small to support the cost structure. Negative stockholders' equity and weak current/quick ratios signal material financial stress.
What is COCHW's revenue and growth?
Envoy Medical, Inc. reported revenue of $166.0K.
Does COCHW pay dividends?
Envoy Medical, Inc. pays dividends, with $1.8M distributed to shareholders in the trailing twelve months.
Where can I find COCHW SEC filings?
Official SEC filings for Envoy Medical, Inc. (CIK: 0001840877) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is COCHW's EPS?
Envoy Medical, Inc. has a diluted EPS of $-0.97.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is COCHW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Envoy Medical, Inc. has a STRONG SELL rating with 96% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is COCHW stock overvalued or undervalued?
Valuation metrics for COCHW: ROE of N/A (sector avg: 15%), net margin of -10,343.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy COCHW stock in 2026?
Our dual AI analysis gives Envoy Medical, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is COCHW's free cash flow?
Envoy Medical, Inc.'s operating cash flow is $-12.5M, with capital expenditures of $7.0K. FCF margin is -7,544.0%.
How does COCHW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -10,343.4% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.64 (avg: 2).